Eribulin in metastatic breast cancer: Real world data.

Clara Luz Fernández-Laguna,Ivan Maray,Lola Macia-Rivas,Cristina Álvarez-Asteinza, Sergio Fernández-Lastras, Veronica Velasco Durántez, Mónica Carbajales Álvarez, Ana Lozan-Blázquez

Breast Disease（2023）

引用 0|浏览1

暂无评分

摘要

The median PFS was similar to that reported previously, with lower OS. There was a tendency to achieve better results when eribulin was used earlier. Eribulin is a less well-tolerated drug than published literature.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要